Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H2 2018, provides an overview of the Chemotherapy Induced Neutropenia (Toxicology) pipeline landscape.
Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain. The predisposing factors include age, co-morbidities and time course of therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chemotherapy Induced Neutropenia (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 7, 6, 8, 5 and 12 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Chemotherapy Induced Neutropenia (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chemotherapy Induced Neutropenia (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chemotherapy Induced Neutropenia (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chemotherapy Induced Neutropenia - Overview
Chemotherapy Induced Neutropenia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chemotherapy Induced Neutropenia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development
BeyondSpring Pharmaceuticals Inc
Biocon Ltd
Bolder Biotechnology Inc
Cellerant Therapeutics Inc
Chong Kun Dang Pharmaceutical Corp
Cinfa Biotech SL
Dr. Reddy's Laboratories Ltd
Gene Techno Science Co Ltd
Generon (Shanghai) Corp Ltd
GlycoMimetics Inc
Hanmi Pharmaceuticals Co Ltd
Lupin Ltd
Mycenax Biotech Inc
Nohla Therapeutics Inc
Pangen Biotech Inc.
Pfizer Inc
Profarma
Prolong Pharmaceuticals LLC
Richter Gedeon Nyrt
Sandoz International GmbH
USV Pvt Ltd
Chemotherapy Induced Neutropenia - Drug Profiles
BBT-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BBT-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dilanubicel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-18 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eflapegrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-627 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GW-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXG-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lenograstim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myelo-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plinabulin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
romyelocel-L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFR-9314 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
uproleselan sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WBI-2100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YPEG-Filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chemotherapy Induced Neutropenia - Dormant Projects
Chemotherapy Induced Neutropenia - Discontinued Products
Chemotherapy Induced Neutropenia - Product Development Milestones
Featured News & Press Releases
Jun 25, 2018: Spectrum Pharmaceuticals to Host Conference Call Highlighting ROLONTIS (eflapegrastim) Phase 3 ADVANCE Study Data Presented at Multinational Association of Supportive Care in Cancer (MASCC)
May 17, 2018: BeyondSpring to Present Positive Data From Prospective Phase 2 Trial Comparing Plinabulin to Neulasta for the Prevention of Chemotherapy-Induced Neutropenia at 2018 ASCO Annual Meeting
May 16, 2018: Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS (eflapegrastim) Published in an ASCO Abstract
Apr 27, 2018: Bolder BioTechnology Announces Positive Results from Phase 1 Clinical Trial of BBT-015, a Long-Acting G-CSF Analog, in Healthy Volunteers
Apr 24, 2018: Enzychem Lifesciences Fast Track Designation for chemo-radiation induced oral mucositis had been granted by the FDA
Apr 17, 2018: BeyondSpring Presents Lead Asset’s Mechanism Data for Prevention of Chemotherapy-Induced Neutropenia
Mar 19, 2018: BeyondSpring Announces Initiation of Phase 3 Clinical Development for Plinabulin for Prevention of Chemotherapy-Induced Neutropenia
Feb 05, 2018: Spectrum Pharmaceuticals Announces ROLONTIS (eflapegrastim) Met the Primary Endpoint in the Phase 3 ADVANCE Study
Feb 05, 2018: BeyondSpring Summarizes Key Messages from KOL Call regarding Lead Asset Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia
Jan 26, 2018: BeyondSpring Presents Promising Data for Lead Asset Plinabulin at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Jan 25, 2018: Generon Successfully Concludes First Phase III Clinical Trial of F-627 for Chemotherapy-induced Neutropenia
Jan 17, 2018: BeyondSpring to Present Data from Phase 2 Portion of Study 105 Phase 2/3 Trial with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Dec 14, 2017: Cinfa Biotech begins US partnering and prepares US development for B12019, a proposed biosimilar to Neulasta (pegfilgrastim)
Dec 14, 2017: BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia
Dec 04, 2017: BeyondSpring’s Lead Asset, Plinabulin, Recognized as 2017 National Science and Technology Major Project in China
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Chemotherapy Induced Neutropenia - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2018
Chemotherapy Induced Neutropenia - Pipeline by Biocon Ltd, H2 2018
Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology Inc, H2 2018
Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics Inc, H2 2018
Chemotherapy Induced Neutropenia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2018
Chemotherapy Induced Neutropenia - Pipeline by Cinfa Biotech SL, H2 2018
Chemotherapy Induced Neutropenia - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2018
Chemotherapy Induced Neutropenia - Pipeline by Gene Techno Science Co Ltd, H2 2018
Chemotherapy Induced Neutropenia - Pipeline by Generon (Shanghai) Corp Ltd, H2 2018
Chemotherapy Induced Neutropenia - Pipeline by GlycoMimetics Inc, H2 2018
Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2018
Chemotherapy Induced Neutropenia - Pipeline by Lupin Ltd, H2 2018
Chemotherapy Induced Neutropenia - Pipeline by Mycenax Biotech Inc, H2 2018
Chemotherapy Induced Neutropenia - Pipeline by Nohla Therapeutics Inc, H2 2018
Chemotherapy Induced Neutropenia - Pipeline by Pangen Biotech Inc., H2 2018
Chemotherapy Induced Neutropenia - Pipeline by Pfizer Inc, H2 2018
Chemotherapy Induced Neutropenia - Pipeline by Profarma, H2 2018
Chemotherapy Induced Neutropenia - Pipeline by Prolong Pharmaceuticals LLC, H2 2018
Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt, H2 2018
Chemotherapy Induced Neutropenia - Pipeline by Sandoz International GmbH, H2 2018
Chemotherapy Induced Neutropenia - Pipeline by USV Pvt Ltd, H2 2018
Chemotherapy Induced Neutropenia - Dormant Projects, H2 2018
Chemotherapy Induced Neutropenia - Dormant Projects, H2 2018 (Contd..1), H2 2018
Chemotherapy Induced Neutropenia - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
